- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02193620
Study of PHN131 in Patients After Surgery
November 23, 2023 updated by: PhytoHealth Corporation
A Randomized, Double Blind, Placebo-controlled, Multiple Dose Study to Assess the Efficacy, Safety and Pharmacokinetics of Oral Nalbuphine, an Oral Soft Capsule, for Post-hemorrhoidectomy Pain Management
The purpose of this study is to assess the effectiveness, safety and pharmacokinetics of Oral Nalbuphine in the treatment of postoperative pain following hemorrhoidectomy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
• Primary Efficacy Endpoint: Pain assessment calculated as the area under the curve of VAS pain intensity scores through 48 hours.
• Secondary Efficacy Endpoints:
- Consumption of diclofenac (Day 1-2) via Intramuscular Injection (IM injection).
- Time from the end of operation to the first IM injection diclofenac dose
- Brief Pain Inventory (BPI).
- Patient satisfaction.
Study Type
Interventional
Enrollment (Actual)
106
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei city, Taiwan, 114
- General Clinical Research Center, Tri-service General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female >= 20 years of age at Screening
- Scheduled to electively undergo 2 or 3-column excisional hemorrhoidectomy
- American Society of Anesthesiology Physical Class 1 - 3
- Clinical lab values twice the upper limit of normal (values of potential clinical concern are detailed in Appendix) or, if abnormal, deemed not clinically significant per the Investigator.
- Ability and willingness to provide informed consent, adhere to the study visit schedule and complete all study assessments and language specific questionnaires.
Exclusion Criteria:
- Body weight less than 40 kg.
- Concurrent fissurectomy.
- Subject is pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test at Baseline.
- Women of childbearing potential disagree to use an acceptable method of contraception (e.g., hormonal contraceptives, IUD, barrier device or abstinence) throughout the study.
- History of hypersensitivity or allergy to amide-type local anesthetics, opioid, or any ingredient of the medications administered in this study.
- Subject has a resting respiratory rate less than 8 per minute and blood oxygen saturation less than 90 mmHg.
- Use of any NSAIDs, selective COX-2 inhibitors, opioid, acetaminophen, selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants (TCA), gabapentin, or pregabalin within three days of surgery.
- Chronic use of opioid medications for more than 14 days in the last 3 months, or non-opioid pain medications more than 5 times per week.
- Use of any long-acting opioid medication within 3 days of surgery or any opioid medication within 24 hours of surgery.
- Current painful physical condition or concurrent surgery requires analgesic treatment in the postoperative period.
- Contraindication to epinephrine or any of the pain-control agents planned for postoperative use.
- Administration of an investigational drug within the longer of 30 days or 5 elimination half-lives of such investigational drug prior to study drug administration.
- Any psychiatric disorder, psychological, medical, or laboratory condition that may interfere with study assessments or compliance.
- Significant medical conditions or laboratory results that may indicate an increased vulnerability to study drugs and procedures, and thus expose the subject to an unreasonable risk as a result of participating in this clinical trial.
- Any clinically significant event or condition uncovered during surgery.
- History of abuse illicit drugs, prescription medicines or alcohol within the past 2 years.
- Known history of anti-HIV antibody positive .
- Failure to pass drug and alcohol screen.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo group
Placebo soft capsules
|
Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
Other Names:
All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
|
Experimental: Study group
PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
|
All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the area under the curve of VAS pain intensity scores
Time Frame: at 1, 2, 3, 4±0.25, 8±0.5, 12±0.5, 16±0.5, 20±0.5, 24±1, 28±1, 32±2, 36±2, 40±2, 44±2, and 48±2 h after the surgery
|
Pain assessment calculated as the area under the curve of VAS pain intensity scores through 48 hours
|
at 1, 2, 3, 4±0.25, 8±0.5, 12±0.5, 16±0.5, 20±0.5, 24±1, 28±1, 32±2, 36±2, 40±2, 44±2, and 48±2 h after the surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Consumption of diclofenac dose
Time Frame: in 48 hours after surgery
|
Consumption of diclofenac (Day 1-2) via Intramuscular Injection (IM injection)
|
in 48 hours after surgery
|
Time of operation to diclofenac dose
Time Frame: in 48 hours after surgery
|
Time from the end of operation to the first IM injection diclofenac dose
|
in 48 hours after surgery
|
Brief Pain Inventory (BPI)
Time Frame: at 24h and 48h after surgery
|
Brief Pain Inventory (BPI)
|
at 24h and 48h after surgery
|
Patient satisfaction
Time Frame: at 48h after surgery
|
Patient satisfaction
|
at 48h after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Chang-Chieh Wu, MD, Tri-Service General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 30, 2013
Primary Completion (Actual)
September 21, 2014
Study Completion (Actual)
February 13, 2019
Study Registration Dates
First Submitted
July 14, 2014
First Submitted That Met QC Criteria
July 15, 2014
First Posted (Estimated)
July 17, 2014
Study Record Updates
Last Update Posted (Actual)
November 27, 2023
Last Update Submitted That Met QC Criteria
November 23, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PH-CP025
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Analgesia Disorder
-
Lumosa Therapeutics Co., Ltd.CompletedPain | Analgesia DisorderTaiwan
-
Lumosa Therapeutics Co., Ltd.CompletedPain | Analgesia DisorderTaiwan
-
Hospital de Clinicas de Porto AlegreUnknownPain | Analgesia DisorderBrazil
-
Medical University of LublinCompletedAnalgesia | Cataract | Ophthalmological DisorderPoland
-
University Hospital, MahdiaCompletedLocal Anesthesia | Analgesia DisorderTunisia
-
Ajou University School of MedicineCompleted
-
Tanta UniversityCompleted
-
Siriraj HospitalCompletedAnalgesia Disorder | Adverse Reaction to Epidural Anesthesia | Anesthetic Complication EpiduralThailand
-
Mansoura UniversityNot yet recruiting
Clinical Trials on Placebo soft capsules
-
Enzychem Lifesciences CorporationCompleted
-
Boehringer IngelheimCompleted
-
Minghui Pharmaceutical (Shanghai) LTDRecruitingRelapsed/Refractory B-cell MalignanciesChina
-
Peking Union Medical College HospitalUnknownCerebral Small Vessel DiseasesChina
-
The Second Hospital of Hebei Medical UniversityUnknownVascular Cognitive Impairment no DementiaChina
-
Enzychem Lifesciences CorporationCompletedFebrile NeutropeniaKorea, Republic of
-
University Hospital MuensterBasilea Pharmaceutica International LtdTerminatedLupus Erythematosus, CutaneousGermany
-
Radboud University Medical CenterAstellas Pharma Europe B.V.CompletedMetastatic Castration Resistant Prostate CancerNetherlands
-
The First Affiliated Hospital of Dalian Medical...RecruitingLong-Term Effects Secondary to Cancer TherapyChina
-
Peking University People's HospitalChinese Association of Plastics and AestheticsRecruitingPostmenopausal Vulvovaginal AtrophyChina